blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2730663

EP2730663 - Genetic factors associated with inhibitor development in hemophilia A [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.01.2024
Database last updated on 20.12.2024
FormerThe patent has been granted
Status updated on  17.02.2023
FormerGrant of patent is intended
Status updated on  29.09.2022
FormerExamination is in progress
Status updated on  05.08.2022
FormerGrant of patent is intended
Status updated on  10.05.2022
FormerExamination is in progress
Status updated on  05.01.2018
Most recent event   Tooltip15.11.2024Lapse of the patent in a contracting state
New state(s): BG		published on 18.12.2024  [2024/51]
Applicant(s)For all designated states
Berntorp, Erik
Lund University
Malmö Centre for Thrombosis and Haemostasis
Skane University Hospital
205 02 Malmö / SE
For all designated states
Astermark, Jan
Centre for Thromosis and Hemostasis
Skane University Hospital Malmö
205 02 Malmö / SE
[2023/12]
Former [2014/20]For all designated states
Berntorp, Erik
Lund University
Malmö Centre for Thrombosis and Haemostasis
Skane University Hospital
205 02 Malmö / SE
For all designated states
Astermark, Jan
Centre for Thromosis and Hemostasis
Skane University Hospital Malmö
205 02 Malmö / SE
Inventor(s)01 / see applicant
...
 [2014/20]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2023/12]
Former [2014/20]Alt, Michael
Bird & Bird LLP
Maximiliansplatz 22
80333 München / DE
Application number, filing date14154482.521.04.2011
[2014/20]
Priority number, dateUS20100326602P21.04.2010         Original published format: US 326602 P
[2014/20]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2730663
Date:14.05.2014
Language:EN
[2014/20]
Type: A3 Search report 
No.:EP2730663
Date:10.09.2014
Language:EN
[2014/37]
Type: B1 Patent specification 
No.:EP2730663
Date:22.03.2023
Language:EN
[2023/12]
Search report(s)(Supplementary) European search report - dispatched on:EP07.08.2014
ClassificationIPC:C12Q1/6883, A61P7/04, A61P37/06
[2022/16]
CPC:
C12Q1/6883 (EP,US); A61P37/06 (EP); A61P7/04 (EP);
C12Q2600/106 (EP,US); C40B30/04 (US)
Former IPC [2014/20]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/12]
Former [2014/20]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Genetische Faktoren im Zusammenhang mit der Hemmerentwicklung bei Hämophilie A[2014/20]
English:Genetic factors associated with inhibitor development in hemophilia A[2014/20]
French:Facteurs génétiques associés au développement d'inhibiteur dans l'hémophilie A[2014/20]
Examination procedure10.03.2015Amendment by applicant (claims and/or description)
10.03.2015Examination requested  [2015/16]
09.01.2018Despatch of a communication from the examining division (Time limit: M04)
22.05.2018Reply to a communication from the examining division
17.07.2018Despatch of a communication from the examining division (Time limit: M06)
28.01.2019Reply to a communication from the examining division
11.05.2022Communication of intention to grant the patent
03.08.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.09.2022Communication of intention to grant the patent
09.02.2023Fee for grant paid
09.02.2023Fee for publishing/printing paid
09.02.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11715562.2  / EP2561090
Divisional application(s)EP23163143.3   Application withdrawn  : 31.05.2023
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.01.2018
Opposition(s)02.01.2024No opposition filed within time limit [2024/09]
Fees paidRenewal fee
10.02.2014Renewal fee patent year 03
10.02.2014Renewal fee patent year 04
27.04.2015Renewal fee patent year 05
27.04.2016Renewal fee patent year 06
27.04.2017Renewal fee patent year 07
25.04.2018Renewal fee patent year 08
18.04.2019Renewal fee patent year 09
21.04.2020Renewal fee patent year 10
21.04.2021Renewal fee patent year 11
20.04.2022Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT22.03.2023
BG22.03.2023
CZ22.03.2023
DK22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
MC22.03.2023
NL22.03.2023
PL22.03.2023
RO22.03.2023
RS22.03.2023
SI22.03.2023
SK22.03.2023
SM22.03.2023
LU21.04.2023
BE30.04.2023
CH30.04.2023
LI30.04.2023
NO22.06.2023
GR23.06.2023
IS22.07.2023
PT24.07.2023
[2024/51]
Former [2024/10]AT22.03.2023
CZ22.03.2023
DK22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
MC22.03.2023
NL22.03.2023
PL22.03.2023
RO22.03.2023
RS22.03.2023
SI22.03.2023
SK22.03.2023
SM22.03.2023
LU21.04.2023
BE30.04.2023
CH30.04.2023
LI30.04.2023
NO22.06.2023
GR23.06.2023
IS22.07.2023
PT24.07.2023
Former [2024/09]AT22.03.2023
CZ22.03.2023
DK22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
MC22.03.2023
NL22.03.2023
PL22.03.2023
RO22.03.2023
RS22.03.2023
SK22.03.2023
SM22.03.2023
LU21.04.2023
CH30.04.2023
LI30.04.2023
NO22.06.2023
GR23.06.2023
IS22.07.2023
PT24.07.2023
Former [2024/08]AT22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
MC22.03.2023
NL22.03.2023
PL22.03.2023
RO22.03.2023
RS22.03.2023
SK22.03.2023
SM22.03.2023
LU21.04.2023
NO22.06.2023
GR23.06.2023
IS22.07.2023
PT24.07.2023
Former [2024/04]AT22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
NL22.03.2023
PL22.03.2023
RO22.03.2023
RS22.03.2023
SK22.03.2023
SM22.03.2023
LU21.04.2023
NO22.06.2023
GR23.06.2023
IS22.07.2023
PT24.07.2023
Former [2023/50]AT22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
NL22.03.2023
PL22.03.2023
RO22.03.2023
RS22.03.2023
SK22.03.2023
SM22.03.2023
NO22.06.2023
GR23.06.2023
IS22.07.2023
PT24.07.2023
Former [2023/49]AT22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
NL22.03.2023
RO22.03.2023
RS22.03.2023
SM22.03.2023
NO22.06.2023
GR23.06.2023
PT24.07.2023
Former [2023/48]AT22.03.2023
EE22.03.2023
FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
NL22.03.2023
RS22.03.2023
SM22.03.2023
NO22.06.2023
GR23.06.2023
PT24.07.2023
Former [2023/46]FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
NL22.03.2023
RS22.03.2023
SM22.03.2023
NO22.06.2023
GR23.06.2023
PT24.07.2023
Former [2023/38]FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
NL22.03.2023
RS22.03.2023
NO22.06.2023
GR23.06.2023
Former [2023/37]FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
RS22.03.2023
NO22.06.2023
GR23.06.2023
Former [2023/36]FI22.03.2023
HR22.03.2023
LT22.03.2023
LV22.03.2023
RS22.03.2023
NO22.06.2023
Former [2023/35]HR22.03.2023
LT22.03.2023
RS22.03.2023
NO22.06.2023
Former [2023/34]LT22.03.2023
RS22.03.2023
Former [2023/33]LT22.03.2023
Documents cited:Search[A]WO2008059009  (CRUCELL HOLLAND BV [NL], et al) [A] 1-18* claim 6 *;
 [XI]  - ASTERMARK JAN ET AL, "Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort", BLOOD, & 51ST ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 05 -08, 2009, (200911), vol. 114, no. 22, page 95, XP055132006 [X] 13,16-18 * the whole document * [I] 1-12,14,15
 [XA]  - AFFYMETRIX, "Data Sheet Affymetrix(R) Genome-Wide Human SNP Array 6.0", INTERNET CITATION, (2007), pages 1 - 4, URL: http://www.affymetrix.com/support/technical/datasheets/genomewide_snp 6_datasheet.pdf, (20090410), XP002525407 [X] 13,16-18 * the whole document * [A] 1-12,14,15
 [A]  - COPPOLA A ET AL, "Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors.", JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH NOV 2009 LNKD- PUBMED:19740093, (200911), vol. 7, no. 11, ISSN 1538-7836, pages 1809 - 1815, XP002637934 [A] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1538-7836.2009.03615.x
 [A]  - SALVIATO R ET AL, "F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors.", HAEMOPHILIA : THE OFFICIAL JOURNAL OF THE WORLD FEDERATION OF HEMOPHILIA JUL 2007 LNKD- PUBMED:17610549, (200707), vol. 13, no. 4, ISSN 1351-8216, pages 361 - 372, XP002637935 [A] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1111/J.1365-2516.2007.01437.X
 [A]  - ROCINO ANGIOLA ET AL, "Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.", HAEMATOLOGICA APR 2006 LNKD- PUBMED:16585022, (200604), vol. 91, no. 4, ISSN 1592-8721, pages 558 - 561, XP002637936 [A] 1-18 * the whole document *
 [A]  - ASTERMARK J ET AL, "Inhibitor development.", HAEMOPHILIA : THE OFFICIAL JOURNAL OF THE WORLD FEDERATION OF HEMOPHILIA JUL 2008 LNKD- PUBMED:18510520, (200807), vol. 14 Suppl 3, ISSN 1365-2516, pages 36 - 42, XP002637937 [A] 1-18 * the whole document *
by applicantUS5210015
 WO9513399
 US5487972
 US6177249
    - SAENKO, TRENDS CARDIOVASC. MED., (1999), vol. 9, pages 185 - 192
    - LENTING ET AL., BLOOD, (1998), vol. 92, pages 3983 - 3996
    - ZHANG, CLINIC. REV. ALLERG. IMMUNOL., (2009), vol. 37, pages 114 - 124
    - OLDENBURG; PAVLOVA, HAEMOPHILIA, (2006), vol. 12, no. 6, pages 15 - 22
    - ZHANG ET AL., CLINIC. REV. ALLERG. IMMUNOD., (2009), vol. 37, pages 114 - 124
    - GOUW; VAN DEN BERG, SEMIN. THROMB. HEMOST., (2009), vol. 35, pages 723 - 734
    - WIGHT ET AL., HAEMOPHILIA, (2003), vol. 9, pages 436 - 463
    - REDING, HAEMOPHILIA, (2006), vol. 12, no. 6, pages 30 - 36
    - OLDENBURG, THROMB HAEMOST, (1997), vol. 77, pages 238 - 242
    - HAY ET AL., THROMB HAEMOST, (1997), vol. 77, pages 234 - 237
    - LIPPERT, THROMB HAEMOST, (1990), vol. 64, pages 564 - 568
    - ASTERMARK ET AL., BLOOD, (2006), vol. 108, pages 3739 - 3745
    - ASTERMARK, BLOOD, (2006), vol. 107, pages 3167 - 3172
    - ASTERMARK ET AL., J. THROMB. HAEMOST., (2007), vol. 5, pages 263 - 265
    - ASTERMARK ET AL., BLOOD, (2006), vol. 107, pages 3167 - 3172
    - PAVLOVA A ET AL., HAEMOPHILIA, (201005), vol. 16, no. 102, pages 107 - 12
    - KUNISAKI ET AL., J. IMMUNOL., (2006), vol. 176, pages 4640 - 4645
    - JAESCHKE ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 6931 - 6935
    - RINC6N; DAVIS, IMMUNOL. REV., (2009), vol. 228, pages 212 - 224
    - MOORE ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 47373 - 47379
    - EL KHOURY ET AL., J. EXP. MED., (2003), vol. 197, pages 1657 - 1666
    - MANNILA ET AL., THROMB. HAEMOST., (2006), vol. 95, pages 420 - 427
    - ANDERSSON ET AL., PROC. NAIL. ACAD. SCI. USA, (1986), vol. 83, pages 2979 - 2983
    - LIEBERMAN, Pharmaceutical Dosage Forms, (1992), vol. 1-3
    - MILLAR DS ET AL., HUM GENET., (199012), vol. 86, no. 2, pages 219 - 27
    - KAZAZIAN HH JR, NATURE, (19880310), vol. 332, no. 6160, pages 164 - 6
    - OSTERTAG EM, ANNU REV GENET., (2001), vol. 35, pages 501 - 38
    - BEAUCAGE; CARUTHERS, TETRAHEDRON LETTS, (1981), vol. 22, pages 1859 - 1862
    - VAN DEVANTER, NUCLEIC ACIDS RES., (1984), vol. 12, pages 6159 - 6168
    - PEARSON; REANIER, J. CHROM., (1983), vol. 255, pages 137 - 149
    - TYAGI ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, page 303
    - LANDEGREN ET AL., GENOME RESEARCH, (1998), vol. 8, pages 769 - 776
    - BOTSTEIN ET AL., AM J HUMAN GENETICS, (1980), vol. 32, pages 314 - 331
    - MEYERS ET AL., METHODS IN ENZYMOLOGY, (1987), vol. 155, pages 501 - 527
    - KEEN ET AL., TRENDS IN GENETICS, (1991), vol. 7, page 5
    - MYERS ET AL., SCIENCE, (1985), vol. 230, pages 1242 - 1246
    - KWOK ET AL., GENOMICS, (1994), vol. 23, pages 138 - 144
    - SEARS ET AL., BIOTECHNIQUES, (1992), vol. 13, pages 626 - 633
    - ZIMMERMAN ET AL., METHODS MOL. CELL BIOL., (1992), vol. 3, pages 39 - 42
    - FU ET AL., NATURE BIOTECH., (1998), vol. 16, pages 381 - 384
    - CHEE ET AL., SCIENCE, (1996), vol. 274, pages 610 - 614
    - DRMANAC ET AL., SCIENCE, (1993), vol. 260, pages 1649 - 1652
    - DRMANAC ET AL., NATURE BIOTECH., (1998), vol. 16, pages 54 - 58
    - FODOR ET AL., SCIENCE, (1991), vol. 251, pages 767 - 777
    - SHELDON ET AL., CLINICAL CHEMISTRY, (1993), vol. 39, no. 4, pages 718 - 719
    - KOZAL ET AL., NATURE MEDICINE, (1996), vol. 2, no. 7, pages 753 - 759
    - M. KANEHISA, NUCLEIC ACIDS RES., (2004), vol. 12, page 203
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.